Natalizumab treatment for early multiple sclerosis-like symptoms
Part of Brain & nervous system, Immune system & allergy clinical trials.
This Phase 2 study tests natalizumab to treat people who have had a first episode of symptoms suggestive of multiple sclerosis. It aims to see whether the treatment can help after early “demyelination” changes are seen on brain MRI.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 55 years old
- You have had a first episode that doctors think could be “clinically isolated syndrome” or definite multiple sclerosis
- Your brain MRI shows at least two spots (lesions) that look like demyelination
- You can attend study visits and complete the required tests
- You are not allergic to Tyruko® (natalizumab) or its ingredients
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called SYS6020 for people with multiple sclerosis that has not improved with standard treatments. The goal is to see if it can slow or stop the disease and improve symptoms.
This trial tests a new treatment called KITE-363 for people with certain autoimmune nerve diseases, such as multiple sclerosis, myasthenia gravis, or chronic inflammatory demyelinating polyneuropathy, that have not responded well to standard therapies. The goal is to see if it is safe and effective.
This early-stage trial tests a combination treatment—a CD20 antibody (which targets certain immune cells) paired with NK042 cell injection (a type of immune cell therapy)—for people with multiple sclerosis. The goal is to evaluate whether this combination is safe and may help slow disease progression.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This trial tests a new way to give the drug ublituximab (an injection under the skin) to people with relapsing multiple sclerosis. It compares different injection sites and a special auto-injector device to see how the body absorbs the drug and if it's safe.
This study tests ublituximab (Briumvi), a treatment given as an infusion, for people recently diagnosed with relapsing MS. The goal is to see if starting this treatment early helps control MS better.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.